Percutaneous coronary revascularization in patients with formerly "refractory angina pectoris in end-stage coronary artery disease" - Not "end-stage" after all

被引:10
|
作者
Jax, Thomas W. [1 ,2 ,3 ,4 ]
Peters, Ansgar J. [4 ]
Khattab, Ahmed A. [5 ]
Heintzen, Matthias P. [6 ]
Schoebel, Frank-Chris [4 ]
机构
[1] Profil Inst Stoffwechselforsch, D-41460 Neuss, Germany
[2] Dortmund Univ Witten Herdecke, Kardiol Klin, Herzentrum Wuppertal, Dortmund, Germany
[3] Dortmund Univ Witten Herdecke, Inst Herz & Kreislaufforsch, Dortmund, Germany
[4] Univ Klinikum Dusseldorf, Kardiol Klin, D-40225 Dusseldorf, Germany
[5] Segeberger Kliniken GmbH, Herz Kreislauf Zentrum, D-23795 Bad Segeberg, Germany
[6] Kardiol Klin, Klinikum Braunschweig, D-38126 Braunschweig, Germany
来源
关键词
TRANSMYOCARDIAL LASER REVASCULARIZATION; CHRONIC TOTAL OCCLUSIONS; RANDOMIZED-TRIAL; MEDICAL THERAPY; DOUBLE-BLIND; FOLLOW-UP; LIGATION; EFFICACY;
D O I
10.1186/1471-2261-9-42
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Patients with refractory angina pectoris in end-stage coronary artery disease represent a severe condition with a higher reduction of life-expectancy and quality of life as compared to patients with stable coronary artery disease. It was the purpose of this study to invasively re-evaluate highly symptomatic patients with formerly diagnosed refractory angina pectoris in end-stage coronary artery disease for feasible options of myocardial revascularization. Methods: Thirty-four Patients formerly characterized as having end stage coronary artery disease with refractory angina pectoris were retrospectively followed for coronary interventions. Results: Of those 34 patients 21 (61.8%) were eventually revascularized with percutaneous interventional revascularization (PCI). Due to complex coronary morphology (angulation, chronic total occlusion) PCI demanded an above-average amount of time (66 +/- 42 minutes, range 25-206 minutes) and materials (contrast media 247 +/- 209 ml, range 50-750 ml; PCI guiding wires 2.0 +/- 1.4, range 1-6 wires). Of PCI patients 7 (33.3%) showed a new lesion as a sign of progression of atherosclerosis. Clinical success rate with a reduction to angina class II or lower was 71.4% at 30 days. Surgery was performed in a total of 8 (23.5%) patients with a clinical success rate of 62.5%. Based on an intention-to-treat 2 patients of originally 8 (25%) demonstrated clinical success. Mortality during follow-up (1-18 months) was 4.8% in patients who underwent PCI, 25% in patients treated surgically and 25% in those only treated medically. Conclusion: The majority of patients with end-stage coronary artery disease can be treated effectively with conventional invasive treatment modalities. Therefore even though it is challenging and demanding PCI should be considered as a first choice before experimental interventions are considered.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Long term intermittent urokinase therapy improves clinical symptoms and hemodynamics in patients with end-stage coronary artery disease and refractory angina pectoris
    Peters, AJ
    Jax, TW
    Neubaur, TER
    Steiner, S
    Tjia, P
    Leschke, M
    [J]. CIRCULATION, 1996, 94 (08) : 1965 - 1965
  • [32] Prognostic impact of combined transmyocardial laser revascularisation and aortocoronary bypass grafting in patients with end-stage coronary artery disease and refractory angina pectoris
    Maisch, B
    Funck, RC
    Herzum, M
    Simon, B
    Menz, V
    Ristic, AD
    Rybinski, L
    Schoenian, U
    Moosdorf, R
    [J]. CIRCULATION, 2000, 102 (18) : 737 - 738
  • [33] Changes in myocardial perfusion after transmyocardial laser revascularization in patients with end-stage angina pectoris
    Kostkiewicz, M
    Rudzinski, P
    Tracz, W
    Dziatkowiak, A
    [J]. CARDIOLOGY, 2000, 94 (03) : 173 - 178
  • [34] Management of Coronary Artery Disease in End-Stage Renal Disease
    Roberts, John K.
    Patel, Uptal D.
    [J]. SEMINARS IN DIALYSIS, 2011, 24 (05) : 525 - 532
  • [35] Antithrombotic treatment in stable coronary syndromes: Long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris
    Schoebel, FC
    Jax, TW
    Fischer, Y
    Strauer, BE
    Leschke, M
    [J]. HEART, 1997, 77 (01) : 13 - 17
  • [36] Decision-making in end-stage coronary artery disease: Revascularization or heart transplantation?
    Hausmann, H
    Topp, H
    Siniawski, H
    Holz, S
    Hetzer, R
    [J]. ANNALS OF THORACIC SURGERY, 1997, 64 (05): : 1296 - 1301
  • [37] PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY (PTCA) IN PATIENTS WITH END-STAGE
    MCCAMPBELL, MP
    CHERTOW, GM
    SCHWAB, SJ
    BASHORE, TM
    LAZARUS, JM
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1995, 6 (03): : 549 - 549
  • [38] ENDARTERECTOMY IN PATIENTS WITH END-STAGE CORONARY-DISEASE
    WALTER, PJ
    ARMBRUSTER, M
    HEHRLEIN, FW
    [J]. THORACIC AND CARDIOVASCULAR SURGEON, 1986, 34 : 79 - 79
  • [39] Evaluation and treatment of coronary artery disease in patients with end-stage renal disease
    McCullough, PA
    [J]. KIDNEY INTERNATIONAL, 2005, 67 : S51 - S58
  • [40] Effectiveness of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With End-Stage Renal Disease
    Krishnaswami, Ashok
    Goh, Anne C. H.
    Go, Alan S.
    Lundstrom, Robert J.
    Zaroff, Jonathan
    Jang, James J.
    Allen, Elaine
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2016, 117 (10): : 1596 - 1603